Number of Panel Genes3

Stickler syndrome, types I, II and III, Marshall syndrome and autosomal recessive Stickler syndrome - Stickler syndrome (types I, II & III) and related Marshall syndrome are autosomal dominantly inherited disorders caused by defects in three genes. Stickler syndrome, type I (classical type, STL1; MIM 108300) is due to mutations in COL2A1.

Stickler syndrome, types I, II and III, Marshall syndrome and autosomal recessive Stickler syndrome - Stickler syndrome (types I, II & III) and related Marshall syndrome are autosomal dominantly inherited disorders caused by defects in three genes. Stickler syndrome, type I (classical type, STL1; MIM 108300) is due to mutations in COL2A1. Stickler syndrome, type II (STL2; MIM 604841) and Marshall syndrome (MIM 154780) are due to mutations in COL11A1. Stickler syndrome, type III (STL3; MIM 184840) is caused by mutations in COL11A2. Autosomal recessive Stickler syndrome is caused by mutations in collagen IX genes.

Stickler syndrome, types I and II

Stickler syndrome, types I and II are characterized by high myopia, retinal detachment, vitreoretinal degeneration, and cataracts. Some patients may have hearing loss, epiphyseal dysplasia and early-onset osteoarthritis. In addition, cleft palate and Robin sequence (cleft palate, small chin and glossoptosis) are seen in about 30% of the patients.

Marshall syndrome

Marshall syndrome patients have hearing loss, myopia (low or high), vitreoretinal degeneration, retinal detachment, cataracts, midfacial hypoplasia, and cleft palate/Robin sequence. These patients may also have epiphyseal dysplasia and early-onset osteoarthritis.

Stickler syndrome, type III

Stickler syndrome, type III is the non-ocular form of the syndrome. Some patients may present predominantly with cleft palate/Robin sequence, hearing loss or early-onset osteoarthritis. Since COL11A2 is not expressed in the eye, these patients do not have eye findings.

Stickler syndrome, autosomal recessive

Autosomal recessive inheritance has been described in some Stickler syndrome families. Individuals in these families were reported to have clinical findings similar to STL1, STL2, and Marshall syndrome. The cause has been documented to be mutations in collagen IX genes. Collagen IX is a heterotrimeric molecule composed of %u03B11(IX), %u03B12(IX) and %u03B13(IX) chains encoded by the COL9A1, COL9A2 and COL9A3 genes. Analysis of the collagen IX genes is indicated in those instances of Stickler syndrome where autosomal recessive inheritance is suspected. Autosomal dominant mutations in the collagen IX genes cause some cases of multiple epiphyseal dysplasia.

Copy number variation (CNV) analysis of the Stickler syndrome genes is also offered as a panel. Additionally, CTGT offers a comprehensive test (both NGS and CNV panels) for these genes. Panel genes are also offered as individual sequencing and deletion/duplication tests unless otherwise indicated.

Gene(s)

COL11A1 COL11A2 COL2A1

Disease Group

Ophthalmology Hearing Disorders Craniosynostosis and Craniofacial Disorders

MIM

108300 604841 614524

Methodology

Billing

CPT Code(s)
81479 x 1

Ordering

Test Code
1666

Additional Test Codes
1337 —Next Generation Sequencing Only, 1665 — Deletion / Duplication Only

Turnaround Time
Typically 2 to 4 weeks from receipt of a sample in the laboratory. All cases involving ongoing pregnancies will be expedited.

Prenatal Specimens
Cultured cells: 2 confluent T-25 flasks derived from amnio or CVS samples
Genomic DNA: minimum of 3 µg (at a concentration of at least 30 ng/µl)

Non-Prenatal Specimens
Whole blood: purple-top (EDTA) tube, minimum of 3 ml
Genomic DNA: a minimum of 3 µg (at a concentration of at least 30 ng/µl)
Fibroblasts: 2 confluent T-25 flasks
Saliva: only samples collected in Oragene DNA Self-Collection Kit or Oragene Saliva Collection Kit for Young Children are accepted

Shipping
Ship all specimen types at room temperature by overnight courier. Do not freeze.

The American Medical Association (AMA) Current Procedural Terminology (CPT) codes published by HNL Lab Medicine are guidelines and are intended for informational purposes only. CPT coding is the exclusive responsibility of the billing entity. HNL Lab Medicine strongly recommends confirmation of CPT codes with third-party payors and/or the AMA. We assume no responsibility for billing errors due to reliance upon CPT codes provided by HNL Lab Medicine.

News

October 28, 2022

Non-Hodgkin Lymphoma FISH Panel Now Available

B-cell lymphoma is a large group of heterogenous disorders and comprises a majority of non-Hodgkin lymphomas.
Read More
October 20, 2022

Genetic testing for Familial Transthyretin Amyloidosis (TTR) NOW AVAILABLE In-House

Hereditary amyloidosis is a life-threatening disorder that can lead to peripheral neuropathy and heart failure.
Read More
August 08, 2022

Familial hypercholesterolemia (FH)

Familial hypercholesterolemia (FH) is a genetic disorder that increases the likelihood of having coronary heart disease at a younger age. Learn about how to determine if you have hypercholesterolemia and what actions you can take to create better outcomes!

Read More
April 11, 2022

Genome Sequencing: A Vital Tool Used in Identifying and Tracking New COVID-19 Variants

Genome sequencing is reading or decoding the complete genetic information i.e. “Genome” of an organism that is encrypted in the form of a very long string called DNA made up of 4 letters, A, T, G, and C. The genome of an organism essentially determines their physical characteristics and ...
Read More
March 03, 2022

The Effect of Genetics on Individual Heart Health: Early Identification of FH Variations to Optimize Treatment

Test must be ordered by a Physician.

Familial hypercholesterolemia (FH) is a genetic disorder that is characterized by abnormally high blood levels of low-density lipoprotein (LDL) cholesterol, sometimes referred to as "bad cholesterol". This condition affects an estimated 1 in 250 people, and increases the likelihood of developing cardiovascular disease. In fact, FH is estimated to be the cause of 2-3% of heart attacks in individuals younger than age 60.

Read More